Chinese Journal of Integrative Medicine

, Volume 12, Issue 2, pp 85–93

Advance in basic and clinical research of Xuezhikang Capsule

  • Lu Zong-liang
  • Xu Zhi-min
  • Kou Wen-rong
  • Zhao Shui-ping
Feature Articles

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    China Coronary Secondary Prevention Study (CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin J Cardiol 2005; 33 (2): 109–115.Google Scholar
  2. 2.
    Kou WR. Review on Bases and clinics of Xuezhikang Capsule. Chin J Intern Med 1998; 37(6): 364–367.Google Scholar
  3. 3.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.CrossRefGoogle Scholar
  4. 4.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.PubMedCrossRefGoogle Scholar
  5. 5.
    The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.CrossRefGoogle Scholar

References

  1. 1.
    China Coronary Secondary Prevention Study (CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin J Cardiol 2005; 33 (2): 109–115.Google Scholar
  2. 2.
    China Medical Tribune, 2005, http: //www.cmt.com.cn/ http: //www.medtrib.com.cn/ http: //www.cmt.org. cn/.Google Scholar
  3. 3.
    Lu ZL, Du BM, Wu YF, et al. Secondary prevention study of coronary heart disease in aged patients using Xuezhikang. Chin J Geriatr 2005; 24 (11): 805–808.Google Scholar

References

  1. 1.
    Kou WR. Review on basic and clinical research of Xuezhikang. Chin J Intern Med 1998; 37(6): 364–366.Google Scholar
  2. 2.
    Kou WR. Survey on basic and clinical research of Xuezhikang. China Prescript Drug 2005; 7: 62–67.Google Scholar
  3. 3.
    Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-in-flammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004; 24: 915–920.CrossRefGoogle Scholar
  4. 4.
    Zhao SP, Liu L, Cheng YC, etal. Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis 168(2003): 375–380.PubMedCrossRefGoogle Scholar
  5. 5.
    China coronary secondary prevention study(CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin JCardiol 2005; 33(2): 109–115.Google Scholar
  6. 6.
    Lu ZL, Du BM, Wu YF, et al. Secondary prevention study of coronary heart disease in aged patients using Xuezhikang. Chin J Geriatr 2005; 24(11): 805–808.Google Scholar
  7. 7.
    Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time coure study in patients with stable angina. Clin Chim Acta 2005; 352(1-2): 217–224.PubMedCrossRefGoogle Scholar

References

  1. 1.
    Yang HB, Tang YS, Xu FY. Effect of Xuezhikang on vascular endothelial function and blood level of nitric oxide and endothelin in patients with hyperlipidemia. Chin J Integr Tradit West Med 2003; 23(1): 13–15.Google Scholar
  2. 2.
    Liu ZG, Yu XY. Effect of Xuezhikang Capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia. Chin J Integr Med 2004; 10(4): 259–262.CrossRefGoogle Scholar
  3. 3.
    Wu JY, Shao HP, Liu YM. Xuezhikang reduces serum soluble adhesion molecules in hyperlipidemics. J Lanzhou Med Coll 2000; 26(1): 10–12.Google Scholar
  4. 4.
    Huang J, Liu CH, Zhang LJ. Effects of Xuezhikang on plasma levels of sICAM-1 and PAI-1 in patients with essential hypertension. J Postgrad Med 2004; 27(1): 19–25.Google Scholar
  5. 5.
    Lu XX, Liang GF. Effects of oxidized low density lipoprotein and Xuezhikang on nitric oxide synthase activity and intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. J Clin Cardiol 2004; 20 (6): 355–357.Google Scholar
  6. 6.
    Yao QH, Cui CZ, Wang JK, et al. Effect of Xuezhikang on blood lipids, serum oxidized low density lipoprotein, C-reactive protein and fibrinogen in patients with unstable angina pectoris. Chin J Integr Tradit West Med 2003; 23 (10): 750–752.Google Scholar
  7. 7.
    Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004; 110: 915–920.PubMedCrossRefGoogle Scholar
  8. 8.
    Wang M, Shen JJ, Huang SE, et al. To compare the effects of different dose Xuezhikang with provastatin on blood lipids and inflammatory factors in patients with acute coronary syndrome. Prev Treat Cardio Cereb Vasc Dis 2005; 5(5): 14–16.Google Scholar
  9. 9.
    Tian JW, Fang Y, Wu LR, et al. The short-term effect of Xuezhikang and atorvastatin on inflammatory factors in patients with acute coronary syndrome. Chin J Pract Chin Modern Med 2004; 4(17): 1745–1747.Google Scholar
  10. 10.
    Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta 2005; 352(1–2): 217–224.PubMedCrossRefGoogle Scholar
  11. 11.
    Liu L, Zhao SP, Cheng YC, et al. Xuezhikang decreases serum lipoprotein (a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003; 49(8): 1347–1352.PubMedCrossRefGoogle Scholar
  12. 12.
    Shi XY, Zhu ZM, Liu YM, et al. Changes of Lipoprotein (a) in patients with atherosclerosis and effects of Xuezhikang treatment on them. Tianjin Med J 2001; 29 (7): 402–404.Google Scholar
  13. 13.
    Qiu YA, Huang SL, Chen YQ, et al. Proapoptotic effect of angiotensin II on cultured endothelial cells and protective effect of Xuezhikang. Acta Acad Med Jiangxi 2005; 45(2): 11–17.Google Scholar
  14. 14.
    Zhang PH, Li P, Hang XN. Inhibitory effect of Xuezhikang on matrix metalloproteinase 2 secreted by macrophage. Chin J Cardiol 2001; 29(8): 497–499.Google Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press 2006

Authors and Affiliations

  • Lu Zong-liang
    • 1
  • Xu Zhi-min
    • 1
  • Kou Wen-rong
    • 1
  • Zhao Shui-ping
    • 2
  1. 1.Fuwai Hospital of Cardiovascular DiseasesChinese Academy of Medical SciencesBeijing
  2. 2.Department of Cardiology, The Second Xiangya HospitalCentral South UniversityChangsha

Personalised recommendations